June 04, 2018
Agios Pharmaceuticals
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 04, 2018
Blueprint Medicines
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
June 04, 2018
CytomX Therapeutics
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probodyâ„¢ Platform and CX-072 at 2018 ASCO Annual Meeting
June 04, 2018
Sesen Bio
Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock